首页> 外文期刊>Journal of Breast Cancer >Radiation Pneumonitis in Breast Cancer Patients Who Received Radiotherapy Using the Partially Wide Tangent Technique after Breast Conserving Surgery
【24h】

Radiation Pneumonitis in Breast Cancer Patients Who Received Radiotherapy Using the Partially Wide Tangent Technique after Breast Conserving Surgery

机译:保乳手术后使用部分切线技术接受放射治疗的乳腺癌患者的放射性肺炎

获取原文
           

摘要

Purpose We assessed the risk of radiation pneumonitis (RP) in terms of dosimetric parameters in breast cancer patients, who received radiotherapy using the partially wide tangent technique (PWT), following breast conservation surgery (BCS). Methods We analyzed the data from 100 breast cancer patients who underwent radiotherapy using PWT. The entire breast, supraclavicular lymph node, and internal mammary lymph node (IMN) were irradiated with 50.4 Gy in 28 fractions. RP was scored on a scale of 0 to 5, based on Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer toxicity criteria. The dosimetric parameters, used in analysis for the ipsilateral lung, were the mean lung dose (MLD), V5 (percentage of lung volume that received a dose of 5 Gy or more)-V50, and normal tissue complication probability (NTCP). Results Of the 100 patients, three suffered from symptomatic RP (symptom grade ≥2), but were relieved by supportive care. The risk of RP was not correlated with the treatment regimen. RP associated mostly with asymptomatic minimal pulmonary radiologic change or mild dry cough developed more frequently in the group with MLD ≥20.5 Gy or NTCP ≥23% than in the group with MLD Conclusion Dosimetric parameters of MLD and NTCP were correlated with the incidence of RP, but the clinical impact was minimal. We suggest that PWT is a safe technique for the treatment of IMN for BCS patients with low risk of symptomatic RP.
机译:目的我们根据剂量参数评估了乳腺癌患者的放射线性肺炎(RP)风险,这些患者在进行保乳手术(BCS)后使用部分宽切线技术(PWT)接受了放疗。方法我们分析了100例接受PWT放射治疗的乳腺癌患者的数据。整个乳房,锁骨上淋巴结和内部乳腺淋巴结(IMN)均以28个部分的50.4 Gy照射。根据放射治疗肿瘤学小组/欧洲癌症研究和治疗组织毒性标准,RP的评分为0到5。用于同侧肺的分析的剂量参数为平均肺部剂量(MLD),V 5 (接受5 Gy或更多剂量的肺体积百分比)-V 50 和正常的组织并发症发生率(NTCP)。结果100例患者中,有3例出现症状性RP(症状≥2级),但通过支持治疗得到缓解。 RP的风险与治疗方案无关。与MLD组相比,MLD≥20.5Gy或NTCP≥23%的组中,与无症状的最小肺部放射学改变或轻度干咳相关的RP发生率更高。但临床影响很小。我们建议,对于有症状性RP风险低的BCS患者,PWT是一种治疗IMN的安全技术。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号